Canadian biotech company Evolved Therapeutics has selected the ENPICOM Platform to accelerate data analysis and candidate selection across its antibody discovery programmes, including next-generation sequencing (NGS) data analysis and clone selection.

Evolved Therapeutics has developed a patented, ultra-high-throughput, function-first antibody discovery platform designed to identify rare monospecific, bispecific and multispecific antibodies with distinctive functional profiles. 

The company said its growing experimental throughput requires digital infrastructure capable of rapidly converting large volumes of discovery data into actionable insights.

Brandon Clavette, VP Research & Development at Evolved Therapeutics, said the company chose ENPICOM because the platform is purpose-built for antibody discovery and reduces the need for scientists to manage complex data handling and bioinformatics workflows.

The ENPICOM Platform integrates sequence and experimental assay data and provides tools for clustering, phylogenetic and enrichment analyses, as well as liability annotation. 

Its built-in visualisation capabilities enable researchers to analyse NGS, Sanger and single B-cell sequencing data and identify candidates for further development without relying extensively on custom coding or dedicated bioinformatics support.

According to ENPICOM, traditional antibody discovery workflows can require weeks of data processing, pipeline development and format reconciliation before researchers can select candidates for follow-up experiments. 

The platform is designed to reduce this bottleneck, with standardised workflows potentially compressing data-handling activities that previously took weeks into a day.

Nicola Bonzanni, Founder and CEO of ENPICOM, said the platform aims to remove the bottleneck between antibody data generation and candidate selection, allowing researchers to move from sequencing data to a shortlist of developable antibody candidates more efficiently.

The collaboration highlights the growing importance of digital and computational infrastructure in high-throughput antibody discovery, particularly as biotechnology companies generate increasingly large volumes of sequencing and experimental data.